NK Cell Chimeric Receptor (SJ-13-0002)



Technology Name
(St. Jude Reference #)
NK Cell Chimeric Receptor (SJ-13-0002)
Description Natural killer (NK) cells rely on surface receptors to distinguish healthy cells from cancer cells. A receptor termed NKG2D-DAP10-CD3ζ was designed and evaluated for its capacity to promote cancer cell killing. Retroviral transduction of NKG2D-DAP10-CD3ζ markedly increased NKG2D surface expression in NK cells, which became consistently more cytotoxic than mock-transduced cells against leukemia and solid tumor cell lines. In contrast, there was no increase in cytotoxicity against non-transformed blood and mesenchymal cells. NKG2D-DAP10-CD3ζ-expressing NK cells had considerable antitumor activity in a mouse model of osteosarcoma, whereas activated NK cells were ineffective. Thus, the cytotoxic potential of NK cells against a wide spectrum of tumor subtypes can be markedly enhanced by expression of NKG2D-DAP10-CD3ζ receptors, making this approach an attractive option for cell therapy of cancer.
Keywords Natural killer (NK) cells, cancer, cell therapy, immunomodulation, chimeric antigen receptor
Granted Patents or Published Applications Provisional application available under confidentiality
Related Scientific References Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D., A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013 Mar 15;73(6):1777-86. Epub 2013 Jan 9.
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.
   

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: January 2014